KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Invested Capital: 2017-2025

Historic Invested Capital for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to $2.5 billion.

  • Amneal Pharmaceuticals' Invested Capital rose 7.09% to $2.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year increase of 7.09%. This contributed to the annual value of $2.3 billion for FY2024, which is 6.71% down from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Invested Capital stood at $2.5 billion for Q3 2025, which was up 19.31% from $2.1 billion recorded in Q2 2025.
  • Amneal Pharmaceuticals' 5-year Invested Capital high stood at $3.1 billion for Q4 2021, and its period low was $403.7 million during Q1 2021.
  • In the last 3 years, Amneal Pharmaceuticals' Invested Capital had a median value of $2.3 billion in 2024 and averaged $2.4 billion.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Invested Capital plummeted by 86.57% in 2021, and later surged by 572.29% in 2022.
  • Over the past 5 years, Amneal Pharmaceuticals' Invested Capital (Quarterly) stood at $3.1 billion in 2021, then declined by 8.83% to $2.8 billion in 2022, then declined by 13.04% to $2.4 billion in 2023, then decreased by 6.71% to $2.3 billion in 2024, then increased by 7.09% to $2.5 billion in 2025.
  • Its last three reported values are $2.5 billion in Q3 2025, $2.1 billion for Q2 2025, and $2.1 billion during Q1 2025.